Phaseline

Targets › JAK3

JAK3 (Tyrosine-protein kinase JAK3): drug programs, companies and trials

16 programs from 14 companies in 184 trials: 80 Phase 2, 46 Phase 3, 38 Phase 1, 20 Phase 4; Immunology, Oncology, Other; next expected readout Nov 2026.

Non-receptor tyrosine kinase involved in various processes such as cell growth, development, or differentiation. Mediates essential signaling events in both innate and adaptive immunity and plays a crucial role in hematopoiesis during T-cells development. (UniProt, P52333)

Open in Phaseline: the race on JAK3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
TakedaTofacitinib
Janus Kinase (JAK) inhibitor
JAK3, JAK1, JAK2, TYK2Phase 4Ulcerative Colitis; Rheumatoid Arthritis; Axial Spondyloarthritis; Oral Lichen Planus …Jul 2027
EisaiFilgotinib Maleate
Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase TYK2 inhibitor
JAK1, JAK2, TYK2, JAK3Phase 4Ulcerative ColitisNov 2027
IncyteRuxolitinib
Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor
JAK1, JAK2, JAK3, TYK2Phase 3NonSegmental Vitiligo; Hidradenitis Suppurativa; Atopic Dermatitis; Graft-versus-host Disease (GVHD) …Nov 2026
AbbVieUpadacitinib
Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor; Tyrosine-protein kinase JAK2 inhibitor
TYK2, JAK3, JAK2, JAK1Phase 3Atopic Dermatitis; Systemic Lupus Erythematosus; Ulcerative Colitis (UC); Crohn's Disease …Nov 2026
PfizerRitlecitinib
Tyrosine-protein kinase JAK3 inhibitor; TEC family kinase inhibitor
JAK3, ITK, BMX, TEC, TXKPhase 3Severe Alopecia Areata; Vitiligo; Stable Nonsegmental Vitiligo; Alopecia Areata …Dec 2026
LEO PharmaDelgocitinib
Janus Kinase (JAK) inhibitor
JAK3, JAK1, JAK2, TYK2Phase 3Lichen Sclerosus; Palmoplantar Pustulosis; Central Centrifugal Cicatricial Alopecia; VitiligoDec 2026
Pfizertofacitinib
Janus Kinase (JAK) inhibitor
JAK3, JAK1, JAK2, TYK2Phase 3Ulcerative ColitisMar 2027
Sun Pharmaceutical IndustriesDeuruxolitinib Phosphate (CTP-543)
Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor
JAK1, JAK2, JAK3, TYK2Phase 3Alopecia AreataMay 2027
AlfasigmaFilgotinib
Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase TYK2 inhibitor
JAK1, JAK2, TYK2, JAK3Phase 3Polyarticular Course Juvenile Idiopathic Arthritis; Juvenile Idiopathic Arthritis (JIA); Ulcerative Colitis; Axial Spondyloarthritis …Jun 2027
Suzhou Zelgen BiopharmaceuticalsJaktinib Hydrochloride Tablet
JAK inhibitor
JAK1, JAK2, JAK3Phase 3Atopic Dermatitis–
M.D. Anderson Cancer CenterRuxolitinib Phosphate
Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor
JAK1, JAK2, JAK3, TYK2Phase 2Splenomegaly; AML; Chronic Lymphocytic Leukemia; T-cell Prolymphocytic Leukemia …Jan 2027
Fudan UniversitySHR-0302
JAK inhibitor
JAK1, JAK2, JAK3Phase 2Relapsed/Refractory Peripheral T Cell LymphomaFeb 2027
City of Hope Medical CenterRuxolitinib Phosphate
Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor
JAK1, JAK2, JAK3, TYK2Phase 2Acute Lymphoblastic Leukemia; Follicular Helper T-Cell Lymphoma; Hematopoietic and Lymphatic System NeoplasmMar 2027
Shixiu WuJAK Inhibitors
Janus kinase inhibitors
JAK1, JAK2, JAK3, TYK2Phase 2Immune Checkpoint Inhibitors (ICI)-Related Dermatitis–
AbbVieTofacitinib
Janus Kinase (JAK) inhibitor
JAK3, JAK1, JAK2, TYK2Phase 1Healthy VolunteersDec 2026
First Affiliated Hospital of Zhejiang UniversityGecacitinib (also known as Jaktinib)
JAK inhibitor
JAK1, JAK2, JAK3Phase 1Acute Graft Versus Host DiseaseDec 2027

Conditions

Atopic Dermatitis (7) Alopecia Areata (6) Ulcerative Colitis (6) Rheumatoid Arthritis (6) Vitiligo (6) Hidradenitis Suppurativa (5) Acute Lymphoblastic Leukemia (4) Rheumatoid Arthritis (RA (3) Ulcerative Colitis Acute (3) Acute Myeloid Leukemia (3) Severe Alopecia Areata (3) Juvenile Idiopathic Arthritis (JIA) (2)

Modalities

small molecule (15), mixed (1)

Companies

Pfizer (2) AbbVie (2) First Affiliated Hospital of Zhejiang University (1) Sun Pharmaceutical Industries (1) Alfasigma (1) Takeda (1) Incyte (1) LEO Pharma (1) Eisai (1) City of Hope Medical Center (1) Shixiu Wu (1) M.D. Anderson Cancer Center (1) Fudan University (1) Suzhou Zelgen Biopharmaceuticals (1)

Related targets

JAK1 (15) JAK2 (15) TYK2 (12) ITK (1) BMX (1) TEC (1) TXK (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.